| Jessica Houghton, LCSW | |
|
739 S White Horse Pike, Suite 10, Audubon, NJ 08106-1659 | |
| (856) 617-4542 | |
| Not Available |
| Full Name | Jessica Houghton |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 739 S White Horse Pike, Audubon, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316236003 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 44SC05501200 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Houghton, LCSW 739 S White Horse Pike, Suite 10, Audubon, NJ 08106-1659 Ph: (856) 617-4542 | Jessica Houghton, LCSW 739 S White Horse Pike, Suite 10, Audubon, NJ 08106-1659 Ph: (856) 617-4542 |
News Archive
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.
One-fifth of women who should receive radiation after a mastectomy are not getting this potentially lifesaving treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
Researchers in the United States have identified a shared genetic architecture between coronavirus disease 2019 (COVID-19) severity and other health conditions.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMed's option in either cash or shares of unregistered common stock at prices ranging from $0.36 to $0.40 per share.
› Verified 7 days ago
Meredith Morgan Beach, LSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 730 S White Horse Pike, Audubon, NJ 08106 Phone: 856-617-4544 | |
Mrs. Mary Antolik, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 618 S White Horse Pike, Audubon, NJ 08106 Phone: 856-546-0021 Fax: 856-546-6167 | |
Katie L Radie, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 261 W Graisbury Ave, Audubon, NJ 08106 Phone: 856-261-6812 |